Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999675 | 1.00 | BCAT1 (0.39) | BCAT1TSHRTRPV4KHKAR | |
| SCHEMBL3237062 | 0.83 | TSHR (0.46) | TSHRTRPV4ARDYRK1AESR2 | |
| SCHEMBL24084229 | 0.81 | PDK2 (0.43) | BCAT1ARESR2CA1CA2 | |
| SCHEMBL24084262 | 0.81 | BCAT1 (0.43) | BCAT1KHKESR2CA1CA2 | |
| SCHEMBL1365376 | 0.79 | AR (0.46) | TRPV4KHKARESR1ESR2 | |
| SCHEMBL2045858 | 0.77 | CES2 (0.34) | ARALDH1A1GAAALOX15 | |
| SCHEMBL16959428 | 0.77 | TAAR1 (0.32) | GAA | |
| SCHEMBL101977 | 0.76 | DYRK1A (0.47) | TSHRTRPV4DYRK1ACA1CA2 | |
| SCHEMBL158537 | 0.76 | BCAT1 (0.49) | BCAT1TSHRTRPV4CA1CA2 | |
| SCHEMBL30443847 | 0.76 | BCAT1 (0.49) | BCAT1TSHRTRPV4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106883147-B | A kind of preparation method of phenyl-pentafluoride formonitrile HCN | 浙江工业大学 | 2018-11-02 | — | — | CN | claimed |
| CN-106883147-A | A kind of preparation method of phenyl-pentafluoride formonitrile HCN | 浙江工业大学 | 2017-06-23 | — | — | CN | claimed |
| CN-102603571-A | Preparation method of 2,4-dichloro-3-cyano-5-fluobenzoic acid | UNIV ZHEJIANG TECHNOLOGY | 2012-07-25 | — | — | CN | claimed |
| CN-102531961-A | Preparation method of 2,6-dichloro-3-fluorobenzonitrile | UNIV ZHEJIANG TECHNOLOGY | 2012-07-04 | — | — | CN | claimed |
| EP-0073372-B1 | PROCESS FOR PRODUCING 2,6-DIFLUOROBENZONITRILE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1984-08-01 | — | — | EP | claimed |
| JP-1294653-A | — | — | None | — | — | JP | disclosed |
| JP-1311052-A | — | — | None | — | — | JP | disclosed |
| EP-4263544-B1 | INDOLO[3.2.1-JK]CARBAZOLE-6-CARBONITRILE DERIVATIVES AS BLUE EMITTERS IN OLEDS | UDC IRELAND LTD (IE) | 2026-05-13 | — | — | EP | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | BOEHRINGER INGELHEIM INT (DE) | 2025-03-27 | — | — | US | disclosed |
| WO-2025027049-A1 | (2S,5R)-5-(HYDROXYMETHYL)MORPHOLINE-2-CARBOXAMIDES AS AGONISTS OF SSTR4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-0270964-B1 | PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES | BAYER AG (DE) | 1992-07-08 | — | — | EP | disclosed |
| EP-0372621-A1 | Preparation of difluorobenzenes containing electron withdrawing substituents | DowElanco (US) | 1990-06-13 | — | — | EP | disclosed |
| JP-H01311052-A | OPTICALLY ACTIVE COMPOUND AND USE THEREOF | NIPPON TELEGR & TELEPH CORP <NTT> | 1989-12-15 | — | — | JP | disclosed |
| JP-H01294653-A | OPTICALLY ACTIVE LIQUID CRYSTAL COMPOUND | NIPPON TELEGR & TELEPH CORP <NTT> | 1989-11-28 | — | — | JP | disclosed |
| US-4868347-A | SOLVENT EXTRACTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| EP-0270964-A2 | Process for obtaining substituted fluorobenzenes | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0073372-B1 | PROCESS FOR PRODUCING 2,6-DIFLUOROBENZONITRILE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1984-08-01 | — | — | EP | disclosed |
| US-4209457-A | Production of halogenated benzonitriles | I.S. C. Chemicals Limited (GB) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | BCAT1 1254/4885TSHR 3599/4885TRPV4 4091/4885 |
| US-20250100981-A1 | Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4 | SSTR4, SSTR5, SSTR2 | BCAT1 3580/4885TSHR 38/4885TRPV4 250/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | BCAT1 1254/4885TSHR 3599/4885TRPV4 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.